Stock listing

NASDAQ:LABT Lakewood-Amedex Biotherapeutics Inc. Stock

Home listing (NASDAQ) of Lakewood-Amedex Biotherapeutics Inc.

Follow Lakewood-Amedex Biotherapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LABT

$0.245 USD +0.005 (+2.0%)

Close on Nov 20, 2026

Past 6 months -97.2% · daily closes, Apr 23, 2026 – Nov 20, 2026, adjusted for splits
Day range
$0.221 – $0.307 USDNov 20, 2026
Volume
57.47M sharesNov 20, 2026
Market cap
$580,337 USDAt the close on Nov 20, 2026 · price × 2.37M shares outstanding
Traded on an average day
$9.01M USDMedian day 328,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lakewood-Amedex Biotherapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LABT · Home$0.245 USD+0.005 (+2.0%)57,471,326$0.232$0.307$0.221$0.240Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LABT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.245+0.005+2.0%$0.232$0.307$0.22157,471,326
$0.240+0.025+11.9%$0.227$0.308$0.1925,039,832
$0.215-0.005-2.2%$0.207$0.269$0.2041,977,326
$0.219-0.063-22.3%$0.258$0.259$0.212874,059
$0.282-0.077-21.4%$0.334$0.339$0.2402,024,462
$0.359-0.041-10.2%$0.373$0.390$0.3501,159,890
$0.400-0.020-4.8%$0.410$0.440$0.3602,731,700
$0.4200.0000.0%$0.360$0.440$0.3504,376,800
$0.420+0.030+7.7%$0.440$0.450$0.37013,547,700
$0.390-0.150-27.8%$0.440$0.490$0.33036,109,700
$0.540+0.350+184.2%$0.380$0.960$0.370753,749,700
$0.190-0.010-5.0%$0.190$0.200$0.170809,100
$0.200+0.010+5.3%$0.180$0.200$0.170880,800
$0.190-0.010-5.0%$0.190$0.200$0.1701,361,400
$0.200-0.040-16.7%$0.200$0.220$0.2001,935,900
$0.240-0.050-17.2%$0.240$0.240$0.2204,128,300
$0.2900.0000.0%$0.280$0.290$0.25024,887,400
$0.290+0.010+3.6%$0.250$0.290$0.2401,423,200
$0.280-0.030-9.7%$0.270$0.280$0.2402,789,800
$0.310-0.180-36.7%$0.350$0.360$0.28040,069,500
$0.490+0.020+4.3%$0.470$0.510$0.460328,400
$0.470-0.110-19.0%$0.550$0.580$0.420658,900
$0.5800.0000.0%$0.580$0.620$0.57099,600
$0.5800.0000.0%$0.580$0.670$0.56093,100
$0.580-0.030-4.9%$0.630$0.630$0.58065,600
$0.610-0.020-3.2%$0.600$0.630$0.580148,300
$0.630-0.060-8.7%$0.670$0.710$0.620133,900
$0.690-0.040-5.5%$0.730$0.730$0.670152,700
$0.730-0.050-6.4%$0.770$0.770$0.730160,700
$0.780-0.010-1.3%$0.790$0.820$0.780118,100
$0.790-0.060-7.1%$0.820$0.830$0.780216,800
$0.850-0.020-2.3%$0.780$0.900$0.7608,498,700
$0.870+0.020+2.4%$0.860$0.870$0.830149,700
$0.850-0.080-8.6%$0.880$0.890$0.820272,200
$0.9300.0000.0%$0.930$0.950$0.910120,500
$0.930-0.030-3.1%$0.940$0.960$0.910170,300
$0.960-0.030-3.0%$0.970$0.980$0.920401,800
$0.990-0.160-13.9%$1.090$1.090$0.9201,288,600
$1.150-0.520-31.1%$2.060$2.130$1.10035,362,700
$1.670-0.160-8.7%$1.850$1.850$1.630176,000
$1.830+0.050+2.8%$1.760$1.850$1.690101,500
$1.780-0.210-10.6%$1.970$2.000$1.780109,800
$1.990-0.060-2.9%$2.080$2.100$1.900128,400
$2.050+0.060+3.0%$1.990$2.080$1.920361,800
$1.990+0.130+7.0%$1.920$2.150$1.890281,200
$1.860-0.230-11.0%$2.040$2.050$1.840125,200
$2.090-0.080-3.7%$2.180$2.180$2.08054,500
$2.170+0.050+2.4%$2.170$2.170$2.07097,300
$2.120-0.100-4.5%$2.250$2.280$2.06056,400
$2.220+0.170+8.3%$2.110$2.230$2.030141,000
$2.050-0.270-11.6%$2.240$2.300$2.030286,600
$2.320+0.140+6.4%$2.200$2.610$2.1305,084,500
$2.180+0.300+16.0%$1.890$2.270$1.890500,000
$1.880-0.020-1.1%$1.880$1.980$1.87090,200
$1.900-0.170-8.2%$2.100$2.160$1.860251,200
$2.070-0.690-25.0%$2.470$2.640$2.060509,100
$2.760+0.260+10.4%$2.680$2.860$2.5303,568,500
$2.500+0.200+8.7%$2.230$2.580$2.22013,655,500
$2.300-0.190-7.6%$2.440$2.440$2.22095,800
$2.490+0.040+1.6%$2.620$2.620$2.350213,500
$2.450+0.160+7.0%$2.230$2.570$2.200377,200
$2.290+0.160+7.5%$2.100$2.350$2.100213,343
$2.130-0.110-4.9%$2.200$2.290$2.10039,957
$2.240+0.050+2.3%$2.180$2.340$2.17070,500
$2.190-0.050-2.2%$2.170$2.240$2.13085,100

Splits

1 split · NASDAQ:LABT · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:LABT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lakewood-Amedex Biotherapeutics Inc. news

Lakewood-Amedex Biotherapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 20 in all · newest Nov 5, 2026 · oldest 2026
Decks
4 decks · latest Oct 21, 2026

Where Lakewood-Amedex Biotherapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LABT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LABTBOATSUnited StatesUSD

Valuation

Price/book 0.2× against a median of 0.2×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.74M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.46

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$920,657US$559,800n/an/an/a6.4×n/a0.0×n/a
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$793,620−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Median of the othersUS$698,128−US$360,7590.1×−3.3×0.2×−558.9%0.0×1.23

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
7.50 USD · Analysts' mean
EPS, year to Dec 2026
-4.96 · 1 analyst

Team and board

Officers

OfficerRole
Kelvin CooperChief Executive Officer, Director
Peter F. CeccacciChief Financial Officer
Thomas BalzerChief Medical Officer

Board

DirectorRole
Doug ManionChairman of the Board
Joseph TuckerDirector
Kelvin CooperChief Executive Officer, Director
Leonard J. DeRomaDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−2.2%
Q2 2026Aug 28, 2026+0.4%
Q1 2026Jun 3, 2026+9.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck22 slidesOct 21, 2026
Investor Presentation (September 2026)Investor deck21 slidesSep 25, 2026
Investor Presentation (July 2026)Investor deck21 slidesJul 15, 2026
Lakewood-Amedex — Investor Presentation (September 2014)Investor deck31 slidesSeptember 2014

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Research and development1.26M2.10M5.53M
Selling, general and administrative2.51M1.92M3.10M
Operating income-3.77M-4.03M-8.64M
Depreciation and amortization120.0K118.6K121.0K
EBITDA-3.65M-3.91M-8.52M
Interest expense1.31K5.00K10.0K
Income before tax-3.85M-4.86M-8.28M
Net income-3.85M-4.86M-8.28M
Earnings per share, basic-5.50-6.94-11.84

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents236.4K681.1K2.53M
Short-term investments03.86M
Current assets305.4K774.0K6.48M
Property, plant and equipment9.22K
Total assets481.6K1.07M6.89M
Accounts payable381.0K166.5K499.1K
Current liabilities2.41M500.6K2.06M
Total debt1.66M
Total liabilities2.45M661.0K2.34M
Shareholders' equity-1.96M409.6K4.56M
Shares outstanding699.6K699.5K699.5K

Cash flow

LineFY2025FY2024FY2023
Cash from operations-1.94M-5.72M-6.82M
Capital spending0-1.85K0
Free cash flow-1.94M-5.73M-6.82M
Cash from financing1.50M-50.0K0
Share buybacks0-50.0K0
Change in cash-444.7K-1.85M-10.6M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026Current reportSEC
8-K · Current reportNov 10, 2026Material contractSEC
8-K · Current reportSep 28, 2026Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveSep 25, 2026Other filingsSEC
S-1 · Registration statementSep 18, 2026Offer documentSEC
DRS · Draft registration statementAug 21, 2026Offer documentSEC
424B3 · ProspectusAug 17, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
All 47 filings
FilingDateTypeFiled with
DEFA14A · Additional proxy materialAug 10, 2026Meeting noticeSEC
DEF 14A · Proxy statementAug 10, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJul 30, 2026Meeting noticeSEC
8-K · Current reportJul 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 23, 2026Big-stake noticeSEC
424B3 · ProspectusJun 22, 2026Offer documentSEC
424B3 · ProspectusJun 22, 2026Offer documentSEC
8-K · Current reportJun 17, 2026Current reportSEC
424B3 · ProspectusMay 26, 2026Offer documentSEC
424B3 · ProspectusMay 26, 2026Offer documentSEC
10-Q · Quarterly reportMay 22, 2026Quarterly reportSEC
424B4 · ProspectusMay 14, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 14, 2026Other filingsSEC
CORRESP · Letter to the SECMay 12, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 8, 2026Other filingsSEC
4 · Change in ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 1, 2026Insider tradeSEC
S-1 · Registration statementMay 1, 2026Offer documentSEC
424B3 · ProspectusApr 30, 2026Offer documentSEC
8-K · Current reportApr 28, 2026Management or board changeSEC
424B4 · ProspectusApr 23, 2026Offer documentSEC
CERT · Exchange's certificate of listingApr 22, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 20, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 17, 2026Other filingsSEC
S-1/A · Registration statement, amendedApr 6, 2026Offer documentSEC
S-1/A · Registration statement, amendedApr 1, 2026Offer documentSEC
S-1/A · Registration statement, amendedMar 11, 2026Offer documentSEC
S-1/A · Registration statement, amendedFeb 12, 2026Offer documentSEC
S-1/A · Registration statement, amendedFeb 4, 2026Offer documentSEC
S-1 · Registration statementJan 9, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedOct 17, 2025Offer documentSEC
DRS · Draft registration statementJul 31, 2025Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lakewood-Amedex Biotherapeutics Inc.’s releases · as of Aug 3, 2026

Common shares
2,369,688
Fully diluted
2,369,688

Fully diluted

LineSharesAs of
Common shares2,369,688Aug 3, 2026

Share count over time

CountShares
Aug 3, 20262,369,688

Open Cap table

Shareholders

HolderStakeSharesDate
LINDESFARNE LLC9.88%203KApr 17, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joseph Tucker
Other companies: Enveric Biosciences, Inc. (Chief Executive Officer, Director · Since at least Sep 16, 2021)
Director · Since at least Apr 24, 2026
Doug ManionChairman of the Board · Since at least Apr 23, 2026
Kelvin CooperChief Executive Officer, Director · Since at least Apr 17, 2026
Leonard J. DeRomaDirector · Since at least Apr 17, 2026
Peter F. CeccacciChief Financial Officer · Since at least Apr 17, 2026
Thomas BalzerChief Medical Officer · Since at least Apr 17, 2026

Open People

Log in to ask 6ix AI your own questions about Lakewood-Amedex Biotherapeutics Inc.